NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

This roundtable series discusses second-line options in patients with B-cell lymphoma, including CAR T-cell therapy, as discussed by key opinion leaders at virtual live events and interviews.

Treating With CAR T-Cell Therapy in Second-Line B-cell Lymphoma

Early Split Between Responders and Others Shown With CAR T in DLBCL

Early Split Between Responders and Others Shown With CAR T in DLBCL

October 01, 2025

During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.

Early Relapsed DLBCL Requires Disease Control to Make CAR T Successful

Early Relapsed DLBCL Requires Disease Control to Make CAR T Successful

September 25, 2025

During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell lymphoma.

Prompt Management of CRS After CAR T for DLBCL Is Essential

Prompt Management of CRS After CAR T for DLBCL Is Essential

August 11, 2025

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Elimination of REMS Program Could Reduce Barriers to CAR T in DLBCL

Elimination of REMS Program Could Reduce Barriers to CAR T in DLBCL

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

© 2025 MJH Life Sciences^®

All rights reserved.